Table 4.
DM (n = 668) |
MetS (n = 1122) |
Neither DM/MetS (n = 2028) |
Total (n = 3818) |
|
---|---|---|---|---|
CHD | ||||
Model 1 | 0.60† | 0.64§ | 0.63‡ | 0.63§ |
Model 2 | 0.67 | 0.70† | 0.70 | 0.69* |
Model 3 | 0.67 | 0.70* | 0.70 | 0.70 |
Model 4 | 0.67 | 0.72 | 0.70 | 0.70 |
CVD | ||||
Model 1 | 0.59‡ | 0.65† | 0.66§ | 0.66§ |
Model 2 | 0.66 | 0.69 | 0.70 | 0.69* |
Model 3 | 0.66 | 0.69 | 0.70 | 0.69 |
Model 4 | 0.67 | 0.70 | 0.71 | 0.70 |
Model 1 (Base model): 10-year ASCVD risk score + race/ethnicity + education + BMI + statin therapy
Model 2: Base model + ln(Agatston)
Model 3: Base model + ln(Volume)
Model 4: Base model + ln(Volume) + CAC Density
Harrell’s c-statistics were compared between model 4 versus model 1, 2 or 3
ASCVD Atherosclerotic cardiovascular disease, BMI Body mass index, CAC Coronary artery calcium, CHD Coronary heart disease, CVD Cardiovascular disease, DM Diabetes mellitus, MetS , Metabolic syndrome
*p < 0.05, †p < 0.01, ‡p < 0.001, § p < 0.0001